Drug & Gene Delivery Devices Market Size & Forecast to 2032

The Drug & Gene Delivery Devices Market is projected to reach USD 2.37 Billion in 2026. It is expected to continue growing at a CAGR of 9.29%, reaching USD 4.05 Billion by 2032.

Drug and gene delivery devices sit at the center of a rapidly evolving therapeutic ecosystem, connecting advanced biologics, precision medicines, vaccines, and cell and gene therapies with patients in clinically controlled, scalable, and user-friendly formats. The category spans autoinjectors, wearable injectors, infusion pumps, inhalation systems, implantable delivery platforms, microneedles, viral vector delivery, non-viral vectors, lipid nanoparticles, electroporation systems, and other enabling technologies that improve dosing accuracy, adherence, stability, and patient access.

Demand is being shaped by the growth of chronic disease management, biologic drug launches, home-based care, specialty pharmaceuticals, and the clinical expansion of gene therapies. Regulatory agencies such as the U.S. FDA and European Medicines Agency continue to emphasize combination-product quality, human factors engineering, device reliability, sterility assurance, and post-market safety, making validated device design and evidence-based delivery performance key differentiators across the drug delivery devices and gene delivery systems landscape.

Transformative Shifts Reshaping Delivery Platforms

The landscape is shifting from hospital-centered administration toward connected, patient-centric, and minimally invasive delivery. Prefilled syringes, autoinjectors, on-body injectors, smart pumps, and digital adherence tools are enabling more therapies to move into outpatient and home-care settings, while biologics with higher viscosities and larger dose volumes are accelerating innovation in wearable and high-force injection systems.

In gene delivery, the industry is moving beyond a reliance on established viral vectors toward optimized adeno-associated virus platforms, lentiviral systems, lipid nanoparticles, polymeric carriers, and targeted non-viral delivery. These shifts are supported by advances in genomic medicine, mRNA technology, payload engineering, and manufacturing analytics, but they also increase the need for scalable production, cold-chain resilience, immunogenicity management, and regulatory-grade characterization.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical accelerator across the drug and gene delivery device lifecycle. In discovery and formulation, AI models help screen excipients, predict nanoparticle behavior, evaluate protein stability, and optimize vector design. In device engineering, machine learning supports simulation-led design, failure-mode analysis, human factors testing, and predictive quality controls that can shorten development cycles when validated against robust experimental data.

AI is also strengthening manufacturing and post-market performance. Computer vision, sensor analytics, and predictive maintenance improve process control for sterile fill-finish, vector production, assembly, and packaging, while real-world data analytics can identify adherence patterns, infusion anomalies, and safety signals. The strongest opportunities are emerging where AI is governed by traceable data, explainable validation, cybersecurity controls, and compliance with evolving FDA, EMA, and international expectations for software, connected devices, and quality management systems.

Key Regional Insights Across Global Markets

Asia-Pacific is advancing as a major region for drug delivery devices and gene delivery technologies due to expanding biologics pipelines, government investment in biotechnology, large patient populations, and rising demand for self-administered therapies. China, Japan, South Korea, India, and Australia are strengthening clinical research, local manufacturing, and regulatory pathways for advanced therapies, while regional cost sensitivity continues to favor scalable, reliable, and value-engineered delivery platforms.

North America remains a leading innovation and commercialization hub, supported by FDA-cleared combination products, advanced biomanufacturing, clinical trial infrastructure, and a large specialty-pharmaceutical ecosystem. Europe benefits from the European Medicines Agency framework, established medtech clusters, strong biosimilar adoption, and advanced therapy medicinal product regulation, while Latin America is advancing through private healthcare expansion, vaccine infrastructure, and gradual adoption of specialty injectable therapies across Brazil, Mexico, and other major healthcare systems.

The Middle East is investing in healthcare modernization, specialty care, medical infrastructure, and localization strategies, particularly in Gulf markets, while Africa presents long-term potential linked to vaccination programs, infectious disease control, and improving cold-chain and primary-care infrastructure. Across all regions, successful market entry depends on regulatory readiness, payer evidence, device usability, temperature-controlled logistics, and partnerships that align innovative delivery technologies with local healthcare delivery models.

Key Group Insights for Strategic Expansion

ASEAN markets are gaining importance as medical tourism, local pharmaceutical production, and regional harmonization efforts improve access to injectable drugs, vaccines, biosimilars, and specialty therapies. The group offers demand for practical, cost-efficient drug delivery devices that can perform reliably in diverse healthcare settings, humid climates, and decentralized care environments.

The GCC is prioritizing healthcare transformation, domestic life sciences investment, and advanced hospital infrastructure, creating opportunities for premium drug delivery devices, connected adherence solutions, and specialty therapy platforms. The European Union remains a regulatory and innovation anchor for combination products and advanced therapy medicinal products, with medical device regulation, pharmacovigilance expectations, data protection rules, and sustainability policy influencing device design, packaging, traceability, and lifecycle management.

BRICS countries combine large patient bases with rising biologics manufacturing capacity and growing public investment in biotechnology, making affordability, technology transfer, local production, and scalable quality systems central to adoption. G7 markets continue to set quality, reimbursement, intellectual property, and clinical-evidence benchmarks for high-value drug and gene delivery platforms, while NATO countries' focus on medical readiness and secure supply chains reinforces demand for resilient manufacturing, stockpiling capabilities, cybersecurity, and dependable injectable and vaccine delivery systems.

Key Country Insights in Drug & Gene Delivery Devices

The United States leads in drug delivery device innovation, combination-product approvals, connected health adoption, and gene therapy commercialization, supported by FDA regulatory pathways, advanced clinical trial networks, and strong specialty pharmaceutical spending. Canada offers a stable regulatory environment, public health system purchasing discipline, and growing biologics adoption, while Mexico is strengthening its role in medtech manufacturing and regional supply chains. Brazil remains Latin America's largest healthcare system, with opportunities tied to biosimilars, vaccines, and injectable therapies that meet public and private payer requirements.

In Europe, the United Kingdom supports life sciences innovation through strong academic and clinical infrastructure, while Germany remains a major medtech and biopharma manufacturing center. France combines advanced hospital networks with public investment in biotechnology, and Italy and Spain contribute established pharmaceutical manufacturing, clinical research, and specialty-care demand. Russia has maintained interest in domestic pharmaceutical production and vaccine platforms, though market access, regulatory navigation, and supply-chain planning require careful risk assessment.

China is scaling biomanufacturing, clinical development, and domestic innovation in biologics and gene delivery, while India is expanding vaccine, biosimilar, and cost-efficient device capabilities. Japan's mature regulatory system and aging population support demand for safe, easy-to-use delivery devices, and South Korea is advancing through biologics manufacturing, digital health, and cell and gene therapy research. Australia provides a strong clinical trial environment, transparent regulation, and demand for high-quality delivery systems across chronic disease and specialty-care applications.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize patient-centric engineering, validated human factors, and lifecycle quality from the earliest stages of device and therapy development. For drug delivery devices, this means designing for dose accuracy, reduced pain, reliable activation, intuitive training, connectivity where clinically useful, and compatibility with high-viscosity biologics. For gene delivery systems, leaders should invest in vector optimization, targeted delivery, scalable analytics, and manufacturing platforms that reduce variability and improve process robustness.

Commercial success will depend on integrated evidence strategies that combine clinical outcomes, usability data, pharmacoeconomic value, and real-world performance. Companies should build regional regulatory intelligence, diversify suppliers for critical components, strengthen cold-chain and sterile manufacturing resilience, and pursue partnerships with biopharma developers, contract development and manufacturing organizations, digital health firms, and healthcare providers to accelerate adoption while maintaining compliance.

Research Methodology and Data Validation

This executive summary is built on a secondary-research framework using publicly available and verifiable sources such as regulatory agency publications, clinical trial registries, peer-reviewed literature, patent databases, healthcare policy documents, pharmacovigilance materials, and international health and trade datasets. Key reference points include FDA and EMA guidance on combination products and advanced therapies, WHO materials on vaccines and access, and recognized public data from organizations such as the World Bank, OECD, and national health agencies.

Insights are synthesized through triangulation across technology trends, regulatory developments, regional healthcare infrastructure, product commercialization patterns, and manufacturing dynamics. The methodology emphasizes data consistency, source credibility, recency, and practical relevance for decision-makers in drug delivery devices, gene delivery technologies, biopharmaceutical manufacturing, medtech investment, and healthcare strategy.

Conclusion: Delivery Innovation as a Competitive Advantage

The drug and gene delivery devices landscape is entering a phase where therapeutic innovation, device usability, digital intelligence, and manufacturing excellence are inseparable. As biologics, mRNA platforms, and cell and gene therapies expand, delivery technologies will determine how effectively advanced medicines reach patients at scale.

Organizations that combine regulatory-grade evidence, patient-centered design, AI-enabled quality systems, resilient supply chains, and region-specific commercialization strategies will be best positioned to create sustainable value. The next competitive advantage will come not only from novel therapies, but from delivery platforms that make those therapies safer, more accessible, more reliable, and more economically sustainable.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Drug & Gene Delivery Devices Market, by Technology

7.1. Hydrogel Based
7.2. Liposomal
7.3. Nanoparticle
7.4. Polymer Based

8. Drug & Gene Delivery Devices Market, by Device Type

8.1. Auto Injector
8.2. Infusion Pump
8.3. Needle Free Injector
8.4. Pen Injector
8.5. Syringe

9. Drug & Gene Delivery Devices Market, by Molecule Type

9.1. Biologic
9.1.1. Monoclonal Antibody
9.1.2. Peptide
9.1.3. Recombinant Protein
9.2. Gene Therapy
9.2.1. Non Viral
9.2.1.1. Lipid Based
9.2.1.2. Polymer Based
9.2.2. Viral Vector
9.2.2.1. Adenoviral
9.2.2.2. Lentiviral
9.2.2.3. Retroviral
9.3. Small Molecule

10. Drug & Gene Delivery Devices Market, by End User

10.1. Clinics
10.2. Home Healthcare
10.3. Hospitals
10.4. Research Laboratories

11. Drug & Gene Delivery Devices Market, by Application

11.1. Controlled Release
11.2. Smart Delivery
11.3. Sustained Release
11.4. Targeted Delivery

12. Drug & Gene Delivery Devices Market, by Therapeutic Area

12.1. Cardiovascular
12.2. Diabetes
12.3. Infectious Diseases
12.4. Oncology

13. Asia-Pacific Drug & Gene Delivery Devices Market
14. Europe Drug & Gene Delivery Devices Market
15. North America Drug & Gene Delivery Devices Market
16. Latin America Drug & Gene Delivery Devices Market
17. Africa Drug & Gene Delivery Devices Market
18. Middle East Drug & Gene Delivery Devices Market
19. NATO Drug & Gene Delivery Devices Market
20. G7 Drug & Gene Delivery Devices Market
21. BRICS Drug & Gene Delivery Devices Market
22. European Union Drug & Gene Delivery Devices Market
23. ASEAN Drug & Gene Delivery Devices Market
24. GCC Drug & Gene Delivery Devices Market
25. China Drug & Gene Delivery Devices Market
26. United States Drug & Gene Delivery Devices Market
27. Japan Drug & Gene Delivery Devices Market
28. India Drug & Gene Delivery Devices Market
29. Germany Drug & Gene Delivery Devices Market
30. United Kingdom Drug & Gene Delivery Devices Market
31. Australia Drug & Gene Delivery Devices Market
32. France Drug & Gene Delivery Devices Market
33. South Korea Drug & Gene Delivery Devices Market
34. Italy Drug & Gene Delivery Devices Market
35. Canada Drug & Gene Delivery Devices Market
36. Russia Drug & Gene Delivery Devices Market
37. Brazil Drug & Gene Delivery Devices Market
38. Mexico Drug & Gene Delivery Devices Market
39. Spain Drug & Gene Delivery Devices Market

40. Competitive Landscape

40.1. Market Concentration Analysis, 2025
40.1.1. Concentration Ratio (CR)
40.1.2. Herfindahl Hirschman Index (HHI)
40.2. Recent Developments & Impact Analysis, 2025
40.3. Product Portfolio Analysis, 2025
40.4. Benchmarking Analysis, 2025

41. Company Profiles

41.1. Abbott Laboratories
41.2. AptarGroup, Inc.
41.3. Bausch + Lomb Incorporated
41.4. Baxter International Inc.
41.5. Becton, Dickinson and Company
41.6. Camurus AB
41.7. Cook Medical LLC
41.8. Elixir Medical Corporation
41.9. Enable Injections, Inc.
41.10. Gerresheimer AG
41.11. Haselmeier GmbH
41.12. Insulet Corporation
41.13. Medtronic plc
41.14. Nipro Corporation
41.15. Owen Mumford Limited
41.16. Phillips-Medisize, LLC
41.17. Santen Pharmaceutical Co., Ltd.
41.18. SCHOTT Pharma AG & Co. KGaA
41.19. SHL Medical AG
41.20. Spectrum Plastics Group
41.21. Stevanato Group S.p.A.
41.22. Tandem Diabetes Care, Inc.
41.23. Teleflex Incorporated
41.24. Terumo Corporation
41.25. West Pharmaceutical Services, Inc.
41.26. Ypsomed Holding AG

List of Figures

FIGURE 1. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 15. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025 VS 2032 (%)
FIGURE 17. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
FIGURE 19. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 21. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 23. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
FIGURE 25. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. ITALY DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. CANADA DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. RUSSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. BRAZIL DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. MEXICO DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. SPAIN DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

List of Tables

TABLE 1. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL HYDROGEL BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL HYDROGEL BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL HYDROGEL BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL LIPOSOMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL LIPOSOMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL LIPOSOMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL NANOPARTICLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL NANOPARTICLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL NANOPARTICLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL POLYMER BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL POLYMER BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL POLYMER BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL AUTO INJECTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL AUTO INJECTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL AUTO INJECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL INFUSION PUMP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL INFUSION PUMP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL INFUSION PUMP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL NEEDLE FREE INJECTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL NEEDLE FREE INJECTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL NEEDLE FREE INJECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL PEN INJECTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL PEN INJECTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL PEN INJECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL SYRINGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL SYRINGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL BIOLOGIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL BIOLOGIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL BIOLOGIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL MONOCLONAL ANTIBODY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL MONOCLONAL ANTIBODY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL PEPTIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL PEPTIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL RECOMBINANT PROTEIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL RECOMBINANT PROTEIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL RECOMBINANT PROTEIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL NON VIRAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL NON VIRAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL NON VIRAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL LIPID BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL LIPID BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL LIPID BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL POLYMER BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL POLYMER BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL POLYMER BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL VIRAL VECTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL VIRAL VECTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL VIRAL VECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ADENOVIRAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ADENOVIRAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ADENOVIRAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL LENTIVIRAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL LENTIVIRAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL LENTIVIRAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL RETROVIRAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL RETROVIRAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL RETROVIRAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL SMALL MOLECULE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL SMALL MOLECULE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL SMALL MOLECULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL CONTROLLED RELEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL CONTROLLED RELEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL CONTROLLED RELEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL SMART DELIVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL SMART DELIVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL SMART DELIVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL SUSTAINED RELEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL SUSTAINED RELEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL SUSTAINED RELEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL TARGETED DELIVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL TARGETED DELIVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL TARGETED DELIVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL DIABETES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL DIABETES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL DIABETES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 127. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 128. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 129. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 130. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 131. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 132. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 133. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
TABLE 134. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 135. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 136. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 137. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 138. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 139. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 140. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 141. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 142. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 143. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 144. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
TABLE 145. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 146. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 147. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 148. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 149. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 150. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 151. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 152. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 153. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 154. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 155. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
TABLE 156. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 157. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 158. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 159. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 160. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 161. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 162. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 163. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 164. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 165. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 166. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
TABLE 167. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 168. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 169. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 170. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 171. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 172. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 173. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 174. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 175. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 176. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 177. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
TABLE 178. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 179. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 180. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 181. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 182. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 183. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 184. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 185. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 186. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 187. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 188. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
TABLE 189. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 190. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 191. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 192. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 193. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 194. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 195. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 196. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 197. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 198. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 199. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
TABLE 200. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 201. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 202. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 203. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 204. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 205. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 206. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 207. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 208. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 209. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 210. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
TABLE 211. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 212. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 213. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 214. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 215. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 216. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 217. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 218. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 219. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 220. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 221. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
TABLE 222. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 223. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 224. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 225. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 226. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 227. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 228. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 229. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 230. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 231. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 232. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
TABLE 233. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 234. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 235. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 236. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 237. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 238. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 239. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 240. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 241. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 242. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 243. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
TABLE 244. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 245. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 246. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 247. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 248. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 249. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 250. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 251. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 252. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 253. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 254. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
TABLE 255. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 256. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 257. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 258. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 259. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 260. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 261. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 262. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 263. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 264. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 265. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
TABLE 266. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 267. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 268. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 269. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 270. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 271. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 272. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 273. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 274. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 275. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 276. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
TABLE 277. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 278. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 279. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 280. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 281. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 282. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 283. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 284. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 285. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 286. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 287. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
TABLE 288. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 289. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 290. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 291. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 292. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 293. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 294. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 295. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 296. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 297. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 298. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
TABLE 299. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 300. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 301. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 302. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 303. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 304. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 305. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 306. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 307. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 308. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 309. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
TABLE 310. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 311. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 312. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 313. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 314. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 315. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 316. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 317. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 318. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 319. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 320. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
TABLE 321. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 322. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 323. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 324. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 325. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 326. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 327. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 328. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 329. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 330. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 331. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
TABLE 332. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 333. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 334. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 335. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 336. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 337. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 338. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 339. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 340. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 341. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 342. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
TABLE 343. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
TABLE 344. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 345. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 346. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 347. ITALY DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 348. ITALY DRUG & GENE DELIVERY DEVICES MARKET SIZE, B

Companies Mentioned

The companies featured in this Drug & Gene Delivery Devices market report include:

Abbott Laboratories
AptarGroup, Inc.
Bausch + Lomb Incorporated
Baxter International Inc.
Becton, Dickinson and Company
Camurus AB
Cook Medical LLC
Elixir Medical Corporation
Enable Injections, Inc.
Gerresheimer AG
Haselmeier GmbH
Insulet Corporation
Medtronic plc
Nipro Corporation
Owen Mumford Limited
Phillips-Medisize, LLC
Santen Pharmaceutical Co., Ltd.
SCHOTT Pharma AG & Co. KGaA
SHL Medical AG
Spectrum Plastics Group
Stevanato Group S.p.A.
Tandem Diabetes Care, Inc.
Teleflex Incorporated
Terumo Corporation
West Pharmaceutical Services, Inc.
Ypsomed Holding AG

Table Information

Report Attribute	Details
No. of Pages	199
Published	June 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 2.37 Billion
Forecasted Market Value ( USD ) by 2032	$ 4.05 Billion
Compound Annual Growth Rate	9.2%
Regions Covered	Global
No. of Companies Mentioned	27

License	Format	Properties	Price
1 - 5 USER LICENSE PDF, Excel and Online Access		This is a 1-5 user license, allowing up to five users have access to the product.	€3225EUR$3,545USD£2,755GBP €3584EUR$3,939USD£3,061GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€4879EUR$5,363USD£4,167GBP €5422EUR$5,959USD£4,630GBP

Drug & Gene Delivery Devices Market by Technology, Device Type, Molecule Type, End User, Application, Therapeutic Area - Global Forecast 2026-2032

Transformative Shifts Reshaping Delivery Platforms

Cumulative Impact of Artificial Intelligence

Key Regional Insights Across Global Markets

Key Group Insights for Strategic Expansion

Key Country Insights in Drug & Gene Delivery Devices

Actionable Recommendations for Industry Leaders

Research Methodology and Data Validation

Conclusion: Delivery Innovation as a Competitive Advantage

Table of Contents

Companies Mentioned

Table Information

Transformative Shifts Reshaping Delivery Platforms

Cumulative Impact of Artificial Intelligence

Key Regional Insights Across Global Markets

Key Group Insights for Strategic Expansion

Key Country Insights in Drug & Gene Delivery Devices

Actionable Recommendations for Industry Leaders

Research Methodology and Data Validation

Conclusion: Delivery Innovation as a Competitive Advantage

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Drug and Gene Delivery Devices - Global Strategic Business Report

Gene Delivery Technologies Market - Global Forecast 2026-2032

Drug and Gene Delivery Devices Market Report 2026

Gene Therapy Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Therapeutic Area, Type of Vector, Type of Therapy, Type of Gene Delivery Method, Route of Administration, Geographical Regions, Leading Players and Sales Forecast

Non-Viral Gene Delivery Technologies Market Report 2026

About the Drug and Gene Delivery Market